LifeSci Capital Initiates Coverage of Sensorion S.A.

Focused on the Treatment of Inner Ear Disorders with Unmet Medical Needs;
Report Available Here: www.lifescicapital.com/equity-research/sensorion/

NEW YORK, NY / ACCESSWIRE / January 3, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Sensorion (Euronext Paris: ALSEN.PA), a French company developing novel therapies for inner ear disorders.

Sensorion is developing oral treatments for acute vertigo crisis and sudden sensorineural hearing loss (SSNHL), two inner ear disorders with limited treatment options. The total global market for therapies to treat inner ear disorders is roughly $10 billion, reflecting the treatment of approximately 144 million patients. The Company has demonstrated proof-of-concept in preclinical models of vertigo and a Phase Ib study, indicating that SENS-111 can reduce the frequency and severity of vertigo symptoms without sedative effects. Sensorion has initiated a Phase II study in patients with acute unilateral vestibulopathy (AUV) and expects to begin dosing patients in the first quarter of 2017. In addition, the Company plans to advance SENS-401 into Phase II development and expects to provide guidance on next steps in the near-term.

In a 30 page Initiation Report, LifeSci Capital explains the Company’s novel treatment approach to acute vertigo crisis, the shortcomings of existing treatments, and the clinical development plans for both SENS-111 and SENS-401.

Dr. Sherman’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Sensorion as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

David Sherman, Ph.D.
Phone: (212) 915-2570
Email: dsherman@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 452127